Rhizopus Allergy: Bread Mold, Cockroach Cross-Reactivity, and Why Shots Don't Exist
Rhizopus is the most common bread mold and the leading cause of mucormycosis worldwide — accounting for ~60% of all cases — but its most clinically useful allergen fact is that Rhi o 1 (44 kDa aspartic protease) cross-reacts with the German cockroach allergen Bla g 2, creating a mold-insect cross-reactivity rarely seen elsewhere in allergology. No controlled SCIT trial exists for Rhizopus.
About Curex’s SCIT program
Curex’s at-home allergy shots (SCIT) are coming soon and focus on the most common environmental allergens:
- • Pollens — tree, grass, weed & ragweed
- • Pet dander — cat & dog
- • Dust mites
- • Molds — Alternaria & mold mix
Rhizopusis covered here for general education and may not be part of Curex’s current treatment set. Join the waitlist and our care team will help confirm your options.
Rhizopus Allergy Immunotherapy: How It Works
Allergy immunotherapy is the only long-term treatment that re-trains the immune system to stop overreacting to rhizopus — rather than just masking symptoms with antihistamines or steroids. By gradually exposing the body to controlled doses of rhizopus allergen, immunotherapy shifts the underlying allergic response and produces relief that often outlasts treatment by 7–10 years.
There are two evidence-based forms of rhizopus immunotherapy used today, both built on the same desensitization principle but delivered very differently.
of sustained relief after a complete immunotherapy course — the only allergy treatment with proven long-term effect after stopping.
Allergy Shots (SCIT)
Weekly injections of rhizopus extract in a clinic, escalating over 3–6 months until a maintenance dose is reached. Continued monthly for 3–5 years. Longest clinical track record for rhizopus allergy.
- Strongest evidence base for severe and polysensitized patients
- Covered by most insurance plans
- Requires 50–100+ in-person clinic visits across the full course
- Or at home with no clinic visits— Curex’s Virtual Shot Room model delivers the same SCIT program with live video supervision by trained Curex clinical staff for the first injection from each new vial or concentration and restarts after gaps or reactions.
Allergy Drops / Tablets (SLIT)
Daily drops or dissolvable tablets containing rhizopus extract, held under the tongue at home. Same desensitization principle, delivered without injections. WHO-recognized as an effective form of allergy immunotherapy since 2001.
- Taken at home — no weekly clinic trips, no needles
- Lower systemic reaction rate than allergy shots
- Curex offers prescription rhizopus immunotherapy drops with allergist oversight
The rest of this page goes deep on allergen-specific immunotherapy with shots — protocol, efficacy data, side effects, and cost. If you’d rather skip the clinic and treat rhizopus allergy with at-home drops, see how Curex sublingual immunotherapy compares below.
What is Rhizopus?
The biology, taxonomy, and clinical fingerprint of Rhizopus — the foundation of how SCIT targets it.
Rhizopus stolonifer — the classic bread mold. Distinguished from Mucor by rhizoids (root-like structures) and stolons. R. arrhizus accounts for ~60% of all mucormycosis cases worldwide.
- Scientific name
- Rhizopus arrhizus (=R. oryzae) / Rhizopus stolonifer
- Family
- MucoraceaeMucorales, Mucoromycetes, Mucoromycota — same phylum as Mucor
- Type
- Outdoor and indoor mold — ubiquitous in soil and on bread; perennial exposure
- Native to
- Cosmopolitan; ubiquitous in soil, decaying organic matter, stored grain, and bread worldwide
- Allergen proteins
- Rhi o 1 (major) — 44 kDa aspartic protease from R. oryzae; WHO/IUIS-designated; cross-reacts with cockroach allergen Bla g 2 (German cockroach aspartic protease) — Wagner S et al., Allergy 2001At least 31 distinct antigens identified in R. nigricans extract by earlier IgE studiesCross-reactivity with spinach and mushroom documented in case reports
- Particle size
- Sporangiospores globose 5–8 µm; rapidly dispersed from sporangia
- Avoidance difficulty
- Moderate
How Rhizopus Allergy Presents
Symptoms by body system — useful for distinguishing Rhizopus sensitivity from overlapping allergies and infections.
Respiratory
- Allergic rhinitis and asthma in IgE-sensitized patients with Rhi o 1 positivity
- Hypersensitivity pneumonitis documented in occupationally exposed grain and food-storage workers
- Rhinocerebral mucormycosis: starts as sinusitis progressing to orbital or cerebral extension — a medical emergency
- Pulmonary mucormycosis in neutropenic patients — haemoptysis and infiltrates
Ocular
- Allergic conjunctivitis in Rhi o 1-sensitized patients during high outdoor exposure
- Orbital extension of rhinocerebral mucormycosis — proptosis and vision loss in immunocompromised patients
- Contact urticaria from decaying food contact in sensitized individuals
Dermal
- Cutaneous mucormycosis at trauma or surgical sites in immunocompromised patients — not IgE-mediated
- Contact urticaria or dermatitis from decaying bread or organic matter in sensitized individuals
- Skin prick test reactions with R. nigricans extract (ImmunoCAP m11)
Systemic
- Disseminated mucormycosis: mortality approaches 100% without early combined surgical and antifungal treatment
- Cross-reactive symptoms mimicking cockroach allergy in urban patients with Rhi o 1 / Bla g 2 cross-sensitization
- Gastric mucormycosis (rare): reported in malnourished or premature-infant patients — not IgE-mediated
The Rhi o 1 and Bla g 2 cross-reactivity is a real diagnostic gotcha — a patient who comes in with apparent dual mold-and-cockroach sensitization might actually have a single aspartic-protease IgE response that reads positive on both tests. Component-resolved diagnostics help untangle this. And in urban housing where both bread mold and cockroaches are real exposures, it also means that cockroach SCIT, which has substantially more outcome data than Rhizopus SCIT, may be the more useful intervention.
Where Rhizopus Triggers Year-Round
Rhizopus is a perennial trigger — exposure is constant for sensitized patients. Geographic intensity still varies by climate.
12-Month Intensity
Year-roundYear-round exposure — outdoor peaks in warm months from soil and decaying organic matter; indoor via stored food, bread, and grain· Perennial; thermotolerant and rapidly growing on virtually any organic substrate
US Exposure Map
0 high-intensity statesExposure intensity by state (text version)
- ME:
- Low
- VT:
- Low
- NH:
- Low
- WA:
- Low
- MT:
- Low
- ND:
- Low
- MN:
- Low
- WI:
- Low
- MI:
- Low
- NY:
- Low
- MA:
- Low
- OR:
- Low
- ID:
- Low
- WY:
- Low
- SD:
- Low
- IA:
- Low
- IL:
- Low
- IN:
- Low
- OH:
- Low
- PA:
- Low
- NJ:
- Low
- CT:
- Low
- RI:
- Low
- CA:
- Low
- NV:
- Low
- UT:
- Low
- CO:
- Low
- NE:
- Low
- MO:
- Low
- KY:
- Low
- WV:
- Low
- VA:
- Low
- MD:
- Low
- DE:
- Low
- AZ:
- Low
- NM:
- Low
- KS:
- Low
- AR:
- Low
- TN:
- Low
- NC:
- Low
- SC:
- Low
- OK:
- Low
- LA:
- Low
- MS:
- Low
- AL:
- Low
- GA:
- Low
- TX:
- Low
- FL:
- Low
- AK:
- Low
- HI:
- Low
What Rhizopus Cross-Reacts With
Patients sensitized to one allergen often react to others sharing similar proteins. This map shows the documented molecular overlaps.
Rhizopus is unique among molds in having a characterized allergen — Rhi o 1 — that cross-reacts with an insect allergen (German cockroach Bla g 2), an unusual mold-arthropod cross-reactivity driven by shared aspartic protease structure.
Close Mucorales relative; broad shared extract antigens across the order; Rhizopus has rhizoids while Mucor does not
Rhi o 1 / Bla g 2 aspartic protease cross-reactivity — the defining feature of Rhizopus allergy diagnostics (Wagner S et al., Allergy 2001 and JACI 2001)
Limited pan-fungal carbohydrate cross-reactivity; different phyla — no characterized component overlap
Is SCIT Right for Your Rhizopus Allergy?
This five-question assessment helps clarify whether your Rhizopus-related concerns are an allergy issue, a cross-reactivity diagnostic question, or a mucormycosis risk evaluation.
Have you tested positive to German cockroach allergen (Bla g 2) alongside Rhizopus?
The Rhizopus SCIT Protocol
Rhizopus SCIT is not commercially available as a standalone extract. Rhizopus is rarely included in mold-mix preparations; when it is, mold-only vial rules from pollens apply (protease degradation), and no evidence defines a therapeutic dose or protocol.
No Rhizopus SCIT protocol exists. When Rhi o 1 / Bla g 2 cross-reactivity is identified, the clinical decision typically centers on cockroach allergen reduction and cockroach SCIT — a well-evidenced intervention — rather than Rhizopus mold immunotherapy. For diabetic or immunocompromised patients, glycemic and immune-status optimization takes priority over any discussion of mold immunotherapy.
Not applicable. If SCIT is pursued for cockroach (via the Bla g 2 pathway), standard cockroach-SCIT maintenance applies — not Rhizopus-specific protocols.
Not applicable for Rhizopus-specific SCIT.
Extract Concentration Ladder
You progress through each vial during build-up. Concentration increases ~10x per step.
What the Research Shows for Rhizopus SCIT
No controlled SCIT trial exists for Rhizopus. The only relevant efficacy data point is for the cross-reactive cockroach allergen — cockroach SCIT has documented real-world outcomes where Rhi o 1 / Bla g 2 cross-reactivity is present.
- Cockroach SCIT — symptom reduction where Bla g 2 cross-reactivity applies45%Wood RA et al., JACI 2014 — cockroach SCIT reduces symptom scores in sensitized inner-city children with asthma; Rhi o 1 / Bla g 2 cross-reactivity means benefit may extend to shared aspartic-protease IgE
No DBPC-RCT exists for Rhizopus SCIT. When Rhi o 1 / Bla g 2 aspartic-protease cross-reactivity is confirmed and cockroach exposure is a driver, cockroach SCIT is more evidence-supported than targeting Rhizopus. The AAAAI/ACAAI Practice Parameter does not list Rhizopus in the recommended mold-allergen panel for immunotherapy.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Rhizopus SCIT Side Effects
Rhizopus SCIT is not prescribed; side-effect data does not exist. If Rhizopus appears in a mold-mix extract, general mold-extract safety patterns apply, including the need for mold-only vials separate from pollens.
Local reactions
4 documented| Reaction | Rate | Severity |
|---|---|---|
Injection-site swelling (general mold extract reference) | Rate 30–50% | Mild |
Large local reaction | Rate 10–20% | Moderate |
Injection-site pruritus | Rate 20–40% | Mild |
Delayed local swelling | Rate 5–15% | Mild |
Systemic reactions
3 documented| Reaction | Rate | Severity |
|---|---|---|
Rhinitis or mild asthma flare | Rate 0.5–2% | Mild |
Generalized urticaria | Rate 0.1–0.5% | Moderate |
Anaphylaxis Onset is almost always within ~30 minutes, so Curex confirms a prescribed epinephrine auto-injector on hand and Zoom-supervises the first injection from each new vial or concentration for any mold SCIT it prescribes | Rate <0.01% | Severe |
Diabetic and immunocompromised patients with positive Rhizopus IgE should not pursue mold immunotherapy without thorough infectious-disease risk stratification — mucormycosis risk assessment and metabolic optimization take precedence over allergy shots.
SCIT vs Alternatives for Rhizopus
For Rhizopus-sensitized patients, the most practical path is: confirm Rhi o 1 / Bla g 2 cross-reactivity, address cockroach exposure (which has SCIT evidence), and pursue standard environmental control and pharmacotherapy for mold-specific symptoms.
| Criterion | SCIT (Rhizopus) | Cockroach SCITBest | Environmental Control | Medications |
|---|---|---|---|---|
| Effectiveness | No evidence — not prescribed | 45% symptom reduction (Wood 2014) — covers shared Bla g 2 pathway | Meaningful — removes Rhizopus and cockroach sources | Symptom control only |
| 5-yr cost | N/A | $3,500–$12,000 over 5 years | Moderate — IPM + HEPA | $500–$2,000/year |
| Duration | N/A | 3–5 years | Ongoing | Indefinite |
| Convenience | N/A | Weekly then maintenance visits | Integrated pest management + HEPA | Daily |
| Safety | Risk concerns in high-risk patients | Standard SCIT safety profile | No injection risk | Generally safe |
| Lasting effect | Unknown | Durable — documented in inner-city asthma trials | Sustained with continued control | No disease modification |
SCIT (Rhizopus)
Cockroach SCITBest
Environmental Control
Medications
When Rhi o 1 / Bla g 2 cross-reactivity is confirmed and cockroach exposure drives symptoms, cockroach SCIT is the most evidence-supported immunotherapy pathway. Curex delivers that cockroach immunotherapy as a self-administered weekly shot at home with pricing confirmed in a current program quote — a personalized serum sterile-compounded to USP <797>, with a prescribed epinephrine auto-injector confirmed on hand and the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff — for eligible patients managing concurrent inhalant allergies while pursuing cockroach environmental control.
What Rhizopus SCIT Actually Costs
Rhizopus-specific SCIT is not covered as a standalone indication. Cockroach SCIT, where clinically indicated based on Bla g 2 component testing and documented exposure, is typically coverable under standard allergy-immunotherapy benefits with appropriate prior-authorization documentation from a board-certified allergist. Curex at-home IgE testing identifies specific rhizopus sensitization before allergist consultations, eliminating the need for an initial skin-test visit.
Cost range varies by deductible, co-insurance, and clinic.
Verify these codes with your insurer to confirm coverage.
See the listed Environmental Allergy Shots Plan rate, commercial terms dated 2026-10-12; consultations are included without copay. Confirm availability, eligibility, other included services, testing, any in-person care, insurance responsibility and billing cadence in your written quote before enrolling.
Join the waitlistStop guessing about your rhizopus allergy. Get a plan.
Take Curex’s 3-minute allergy quiz. A board-certified allergist will review your symptoms and recommend the right immunotherapy path for you — shots or drops.
Free quiz · Board-certified allergists · 50,000+ patients treated · HSA/FSA eligible
Rhizopus SCIT — Frequently Asked
Quick answers to the questions patients ask most before starting treatment.
Rhi o 1 is a 44 kDa aspartic protease produced by Rhizopus oryzae — the only WHO/IUIS-recognized allergen for the entire Rhizopus genus. Its clinical importance lies in a cross-reactivity with Bla g 2, the German cockroach major aspartic protease allergen. Both proteins belong to the same aspartic protease structural family, and IgE directed against one can bind the other. Wagner S et al. documented this cross-reactivity in both JACI 2001 and Allergy 2001. In practical terms: a patient in urban housing who tests positive on both a Rhizopus mold panel and a cockroach allergen panel may actually have one aspartic-protease IgE response rather than genuine dual sensitization. Component testing with Bla g 2 and Rhi o 1 (where available) can differentiate genuine polysensitization from cross-reactivity. This matters because cockroach allergen reduction plus cockroach SCIT has documented clinical evidence — while Rhizopus SCIT does not exist.
Yes — Rhizopus stolonifer (black bread mold) is one of the most recognizable Rhizopus species, producing the fuzzy black growth on bread, fruit, and other high-moisture foods. R. arrhizus (also called R. oryzae) is the most clinically important species — it accounts for approximately 60% of all mucormycosis cases worldwide and is the source of the characterized allergen Rhi o 1. Rhizopus grows on virtually any moist organic substrate: bread, fruit, berries, cooked food, grain, and organic soil debris. The visible black fungal growth is a sporangium (spore sac). For allergically sensitized patients, discarding moldy food promptly and maintaining proper refrigeration and food storage reduces domestic Rhizopus exposure.
Rhizopus arrhizus accounts for approximately 60% of all mucormycosis cases worldwide, compared to a smaller percentage for Mucor and other Mucorales. R. arrhizus has several virulence factors that make it particularly dangerous: it is thermotolerant (grows at 37°C and higher), produces a high-affinity iron permease that allows it to scavenge iron from host tissue, and grows extremely rapidly once established in tissue. In diabetic ketoacidosis, acidosis releases free iron from transferrin — providing the iron substrate that R. arrhizus exploits. The combination of rapid growth, iron scavenging, and thermotolerance makes Rhizopus the dominant Mucorales pathogen in DKA-associated mucormycosis, which accounts for the largest share of cases worldwide. R. arrhizus remained the dominant causative agent throughout the 2021 India COVID-associated epidemic with more than 14,800 cases.
No — standalone Rhizopus SCIT is not prescribed and not commercially available as a validated extract. Rhizopus does not appear in the AAAAI/ACAAI Practice Parameter's recommended mold-allergen panel for immunotherapy. While Rhi o 1 is WHO/IUIS-recognized, no DBPC-RCT has been conducted for Rhizopus SCIT, and no FDA-standardized extract exists. ImmunoCAP m11 (R. nigricans) is available for diagnostic IgE testing only. When allergists encounter a patient with positive Rhizopus IgE alongside cockroach sensitivity, the more clinically actionable path is confirming Bla g 2 cross-reactivity and pursuing cockroach SCIT and environmental control — rather than seeking a Rhizopus-specific immunotherapy product that does not exist.
Both are Mucorales molds in phylum Mucoromycota, but they differ in morphology and allergen characterization. Rhizopus has rhizoids (root-like structures anchoring to substrate) and stolons (runner-like hyphae between sporangia); Mucor lacks rhizoids. Rhizopus sporangiospores are 5–8 µm while Mucor's are slightly larger at 7–8 µm. In allergen terms, Rhizopus has one WHO/IUIS-characterized allergen (Rhi o 1) while Mucor has none. Clinically, Rhizopus accounts for approximately 60% of all mucormycosis cases while Mucor accounts for a smaller but meaningful proportion. In treatment, both infections are treated identically (liposomal amphotericin B plus surgical debridement), and both are voriconazole-resistant — the key distinction from Aspergillus.
Cross-reactivity between Rhizopus and certain foods has been documented in case reports — specifically spinach and mushrooms. This reflects shared allergen proteins between Rhizopus and these food sources rather than mold contamination of the food. However, the clinical significance of this cross-reactivity for most Rhizopus-sensitized patients is not well established, and population-level prevalence data is not available for Rhizopus-food OAS syndromes the way it is for pollen-food allergy syndromes. Patients with documented severe Rhizopus IgE sensitization who experience oral or systemic symptoms after eating mushrooms or spinach should discuss this with their allergist for individual risk assessment. There is no universal recommendation to avoid these foods based on Rhizopus IgE alone.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.